Cargando…
Effect of dihydropyrimidine dehydrogenase single nucleotide polymorphisms on prognosis of breast cancer patients with chemotherapy
Defining biomarkers that predict therapeutic effects and adverse events is a crucial mandate to guide patient selection for personalized cancer treatments. DPD (dihydropyrimidine dehydrogenase, encoded by DPYD gene) is the initial and rate-limiting enzyme of metabolic pathway of fluoropyrimidines, a...
Autores principales: | Qin, Fengxia, Zhang, Huikun, Huang, Yong, Yang, Limin, Yu, Feng, Liu, Xiaoli, Fu, Li, Gu, Feng, Ma, Yongjie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762379/ https://www.ncbi.nlm.nih.gov/pubmed/29340111 http://dx.doi.org/10.18632/oncotarget.23033 |
Ejemplares similares
-
Low expression of BMPRIB indicates poor prognosis of breast cancer and is insensitive to taxane-anthracycline chemotherapy
por: Dai, Kun, et al.
Publicado: (2015) -
Expression of aquaporin1, a water channel protein, in cytoplasm is negatively correlated with prognosis of breast cancer patients
por: Qin, Fengxia, et al.
Publicado: (2016) -
High Expression of Complement Component C7 Indicates Poor Prognosis of Breast Cancer and Is Insensitive to Taxane-Anthracycline Chemotherapy
por: Zhang, Huikun, et al.
Publicado: (2021) -
Dihydropyrimidine dehydrogenase (DPD) polymorphisms knocking on the door
por: Donadio, Mauro Daniel Spina, et al.
Publicado: (2022) -
Low Expression of Slit2 and Robo1 is Associated with Poor Prognosis and Brain-specific Metastasis of Breast Cancer Patients
por: Qin, Fengxia, et al.
Publicado: (2015)